Vulvar and vaginal cancers are relatively rare cancers, but their incidence is increasing worldwide. Overall, 78% of vaginal cancers and 25% of vulvar cancers are associated with Human papillomavirus (HPV) infection. Immunization could be an option for the management of these cases. We researched and assessed the evidence on the efficacy of HPV vaccination administered to women previously treated with surgery, radiotherapy, or chemotherapy with respect to the recurrence of vulvovaginal disease. From 2006 to November 2022, only one study evaluated the efficacy of HPV vaccination with respect to preventing vulvovaginal recurrences in treated women and showed that a quadrivalent HPV vaccine administered after the surgical treatment of vulvar high-grade squamous intraepithelial lesion (HSIL) can reduce vulvar recurrence of the disease. Therefore, the efficacy of HPV vaccination with respect to vulvovaginal recurrence is still an unexplored field. Further studies are needed to produce stronger evidence in order to appropriately support interventions to protect women’s health.

Efficacy of HPV Vaccination Regarding Vulvar and Vaginal Recurrences in Previously Treated Women: The Need for Further Evidence / Bechini A.; Moscadelli A.; Velpini B.; Bonito B.; Orlando P.; Putignano P.; Posi S.; Stacchini L.; Bonanni P.; Boccalini S.. - In: VACCINES. - ISSN 2076-393X. - ELETTRONICO. - 11:(2023), pp. 1084.0-1084.0. [10.3390/vaccines11061084]

Efficacy of HPV Vaccination Regarding Vulvar and Vaginal Recurrences in Previously Treated Women: The Need for Further Evidence

Bechini A.;Moscadelli A.;Velpini B.;Bonito B.;Orlando P.;Putignano P.;Posi S.;Stacchini L.;Bonanni P.;Boccalini S.
2023

Abstract

Vulvar and vaginal cancers are relatively rare cancers, but their incidence is increasing worldwide. Overall, 78% of vaginal cancers and 25% of vulvar cancers are associated with Human papillomavirus (HPV) infection. Immunization could be an option for the management of these cases. We researched and assessed the evidence on the efficacy of HPV vaccination administered to women previously treated with surgery, radiotherapy, or chemotherapy with respect to the recurrence of vulvovaginal disease. From 2006 to November 2022, only one study evaluated the efficacy of HPV vaccination with respect to preventing vulvovaginal recurrences in treated women and showed that a quadrivalent HPV vaccine administered after the surgical treatment of vulvar high-grade squamous intraepithelial lesion (HSIL) can reduce vulvar recurrence of the disease. Therefore, the efficacy of HPV vaccination with respect to vulvovaginal recurrence is still an unexplored field. Further studies are needed to produce stronger evidence in order to appropriately support interventions to protect women’s health.
2023
11
0
0
Goal 3: Good health and well-being
Goal 5: Gender equality
Bechini A.; Moscadelli A.; Velpini B.; Bonito B.; Orlando P.; Putignano P.; Posi S.; Stacchini L.; Bonanni P.; Boccalini S.
File in questo prodotto:
File Dimensione Formato  
vaccines-11-01084-v2.pdf

accesso aperto

Descrizione: Pdf vaccines 11-01084
Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 844.22 kB
Formato Adobe PDF
844.22 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1357116
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact